Global Electronic Drug Delivery Systems Market Size study & Forecast, by Type (Wearable Infusion Pumps, Autoinjectors, Injection Pens and Inhalers), by Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD and Other Indications)

Global Electronic Drug Delivery Systems Market Size study & Forecast, by Type (Wearable Infusion Pumps, Autoinjectors, Injection Pens and Inhalers), by Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD and Other Indications) and Regional Analysis, 2022-2029

Global Electronic Drug Delivery Systems Market is valued approximately USD 9.25 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.9% over the forecast period 2022-2029. Electronic drug delivery systems are portable devices that offer convenient options to patients, such as easy drug administration, dose accuracy, short administration time, and improved patient adherence. The Electronic Drug Delivery Systems market is expanding because of factors such as rising diabetes prevalence and growing geriatric population. It's an oligopolistic market dominated by Novo Nordisk A/S, and AstraZeneca PLC.

Diabetes is one of the world's fastest-growing chronic diseases. Its prevalence has progressively increased during the last few decades. According to the World Health Organization, diabetes will afflict 537 million adults globally in 2021, with one in ten experiencing other diabetes. Furthermore, geriatric, and obese populations are predisposed to chronic diseases. According to the World Bank Group, the world old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Another important component driving space is the rising technological advancements in development of smart drug delivery systems. As per Statista, the market size of drug delivery devices across India was forecasted to value around USD 510 million by 2023. In addition, in 2019, the total global cell and gene drug delivery devices market was dominated by North America and Europe, which were responsible for than 83 % of the market all together. It was forecast that this domination will continue until 2030. However, availability of alternative drug delivery modes stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Electronic Drug Delivery Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the Increased demand for advanced drug delivery systems such as metered-dose inhalers and sensor-embedded devices. According to the Statista, as of 2021, the United States' share of the total global biotech value stood at nearly 59 %, while China had around 11%. Furthermore, Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an rise in diabetic patients and the high demand for advanced healthcare services in the market space.

Major market player included in this report are:

Biogen Inc
United Therapeutics Corporation
Medtronic PLC
Bayer AG
Insulet Corporation
Novo Nordisk
Companion Medical
F.Hoffmann-La Roche, Ltd.
Amgen, Inc.
AstraZeneca PLC

Recent Developments in the Market:
 In January 2023, Biogen partnered with Alcyone Therapeutics to improve the delivery of its spinal muscular atrophy drug Spinraza, handing over USD 10 million upfront for a global license to an implantable device. It is delivered via intrathecal injection, also known as lumbar puncture. The route of delivery gets the antisense oligonucleotide into the cerebrospinal fluid and thereby provides direct access to motor neurons in the central nervous system. But intrathecal injections can be uncomfortable for patients and require travel to hospitals or outpatient clinics.

Global Electronic Drug Delivery Systems Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Indication, Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Wearable Infusion Pumps
Autoinjectors
Injection Pens
Inhalers
By Indication:
Diabetes
Multiple Sclerosis
Cardiovascular Disease
Asthma & COPD
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Biogen Inc
United Therapeutics Corporation
Medtronic PLC
Bayer AG
Insulet Corporation
Novo Nordisk
Companion Medical
F.Hoffmann-La Roche, Ltd.
Amgen, Inc.
AstraZeneca PLC

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.